Cytokinetics Inc was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its advanced research and development programs relates to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. It also conducts earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. Its drug candidate from its skeletal muscle contractility program, tirasemtiv, formerly known as CK-2017357, is a fast skeletal muscle troponin activator. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil, formerly known as CK-1827452, is a novel cardiac muscle myosin activator that is being developed under a strategic alliance with Amgen. It is conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. The Company is currently conducting a Phase II clinical trials program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS, Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS. It is also developing CK-2127107, a structurally distinct, fast skeletal muscle troponin activator, under a strategic alliance with Astellas. The Company competes with Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., BrainStorm Cell Therapeutics and Neuralstem. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.